Systemic lupus erythematosus
Conditions
Interventions
Experimental group (Telitacicept):None
Control group (conventional treatment):None
Sponsors
The Second Affiliated Hospital of Shantou University Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for systemic lupus erythematosus; patients with lupus nephritis meet the 2021 Clinical Practice Guidelines for the Management of Glomerular Diseases to Improve Global Kidney Disease Outcomes for Lupus Nephritis classification criteria; 2. Age >=16 years and =4 weeks.
Exclusion criteria
Exclusion criteria: 1.Age =65 years; 2.Known hypersensitivity to the active substance or any excipients of Telitacicept; 3.Duration of Telitacicept treatment <4 weeks; 4.Presence of other concomitant autoimmune diseases; 5.Malignancy; 6.Severe infectious diseases; 7.Neuropsychiatric lupus encephalopathy; 8.Pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein/urine creatinine ratio;Qualitative urine protein;Occult blood in urine;Albumin;globulin;creatinine;urea;complement C3;complement C4;immunoglobulin A;immunoglobulin M;immunoglobulin G;anti-double stranded DNA antibody (anti-dsDNA);antinuclear antibody (ANA);anti-extractable nuclear antigen antibody (anti-ENA); | — |
Secondary
| Measure | Time frame |
|---|---|
| triglycerides;total cholesterol;C-reactive protein;white blood cell count (WBC);hemoglobin (Hb);low-density lipoprotein;calcium;phosphorus; | — |
Countries
China
Contacts
Public ContactTianbiao Zhou
The Second Affiliated Hospital of Shantou University Medical College
Outcome results
None listed